Publication Category

The intersection of risk and benefit: is warfarin anticoagulation suitable for atrial fibrillation in patients on hemodialysis

Dr. Claudio Rigatto

Sood MM, Komenda P, Sood AR, Rigatto C, Bueti J.


Abstract: In patients with ESRD who are undergoing hemodialysis, the rates for both stroke and bleeding are 3 to 10 times higher than that for the general population. Furthermore, the proportion of hemorrhagic to ischemic strokes has increased, making the decision of whether to initiate anticoagulation problematic. In this commentary, we discuss the existing literature for stroke in atrial fibrillation, stroke type, risk reduction with anticoagulation, and bleeding risks in the hemodialysis population. We comment on validated risk stratification models of stroke prevention and bleeding and their applicability to patients undergoing hemodialysis. Finally, we recommend treatment strategies that are based on the existing state of knowledge.

Research Division · Seven Oaks Chronic Disease Innovation Centre
2300 McPhillips Street · Winnipeg, Manitoba · R2V 3M3 · 204‑631‑3834